Core Insights - Cartesian Therapeutics is advancing its lead cell therapy candidate, Descartes-08, for autoimmune diseases, with significant progress in clinical trials and strategic priorities for 2026 [1][2][9] Group 1: Clinical Trials and Developments - Enrollment is on track for the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG), which is designed to assess the therapy against a placebo in approximately 100 participants [3] - The Phase 2 trial for myositis is set to begin in the first half of 2026, with a seamless adaptive design allowing for a potential single pivotal trial after an interim analysis [2][3] - A Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis has been initiated, with the therapy previously granted Rare Pediatric Disease Designation by the FDA [4][8] Group 2: Mechanism of Action and Efficacy - Descartes-08 targets B-cell maturation antigen (BCMA) and has shown deep and durable responses in MG patients, with 57% of participants achieving minimal symptom expression by Month 6 and maintaining it through Month 12 [5] - The therapy has demonstrated a favorable safety profile, with no instances of cytokine release syndrome or neurotoxicity reported, supporting its outpatient administration [5][8] Group 3: Financial Outlook - The company expects its current cash resources to support operations, including the ongoing Phase 3 trial and the initiation of the Phase 2 myositis trial, through mid-2027 [7] Group 4: Strategic Initiatives - Cartesian is exploring enhanced delivery platforms for its cell therapies, including agreements to optimize in-vivo delivery of Descartes-08 and next-generation agents [6] - The appointment of Adrian Bot, M.D., Ph.D., to the Board of Directors is aimed at supporting the strategic expansion of the company's cell therapy initiatives [6]

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment.Capricor Therapeutics (CAPR 2.85%) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence. The move followed the company's announcement of positive top-line results from a Phase 3 trial of Deramiocel, a cell therapy for the treatment of Duchenne muscular dystrophy (DMD). However, the story is not quite as simple as a ...

HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference taking ...

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. has announced that its registration statement for a merger with Z Squared Inc. has been declared effective by the SEC, and it will begin mailing the definitive proxy statement/prospectus to stockholders ahead of the Stockholder Meeting scheduled for January 30, 2026 [1] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [3] - The company operates through its subsidiaries, including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies [3] Therapeutic Portfolio - Coeptis's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [4] - The company is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [4] Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [5] Z Squared Overview - Z Squared is focused on building a sustainable cryptocurrency mining operation, with 9,000 ASIC miners targeting Dogecoin and Litecoin, addressing market caps of $20 billion and $6 billion respectively [7] Stockholder Meeting - The Stockholder Meeting for the merger transaction will be held on January 30, 2026, with notices being mailed to stockholders of record as of January 2, 2026 [1]

Lineage's exclusive option and license agreement (the "Agreement†) with Factor was announced in 2023. The novel hypoimmune iPSC line received by Lineage contains a set of specific edits selected in a development strategy vetted with subject matter experts in the U.S. and abroad, as well as under a broader competitive landscape analysis. The edits include: the targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8 ...

Group 1 - ProKidney Corp. is a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD) [1] - The CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [2] - ProKidney's lead product candidate, rilparencel (REACT), is a first-in-class autologous cell therapy aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes [3] Group 2 - The ongoing Phase 3 REGEN-006 (PROACT 1) study is evaluating the potential of rilparencel to improve kidney function [3] - ProKidney was founded in 2015 after a decade of research in cell therapy for CKD [3] - The live webcast of the presentation will be accessible through ProKidney's website, with a replay available for 30 days post-event [2]

EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors section of th ...

Announcement Highlights: MELBOURNE, Australia, Dec. 14, 2025 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that patient enrolment has been completed in its Phase 2 clinical trial of CYP-001 in adults with newly diagnosed, high risk acute graft versus host disease (aGvHD). A total of 65 participants have been enrolled in the trial across numerous clinical centres in the US, Europe and Aust ...

Summary of Bristol-Myers Squibb Company (NYSE:BMY) Hematology Drug Development Update Company Overview - **Company**: Bristol-Myers Squibb Company (BMS) - **Focus**: Hematology treatments, specifically advancements in drug development for multiple myeloma and other hematological diseases Key Points and Arguments Strategic Approach to Drug Development - BMS emphasizes a strategic approach in drug development focusing on hematology, leveraging strong scientific expertise and innovative research platforms [4][5] - The company is committed to three key priorities: science, execution, and value, ensuring that resources are allocated to the most promising growth opportunities [6][7] Hematology Leadership - BMS has a strong legacy in hematology, being the first company with two approved CAR-T cell therapies (Abecma and Breyanzi) in distinct disease areas [8] - The company is advancing its leadership in targeted protein degradation and cell therapy, with a focus on innovative treatments for hematological diseases [9][10] Pipeline and Portfolio - BMS has a diverse hematology portfolio, including multiple myeloma, leukemias, lymphomas, and anemia, with critical assets in both late and early stages [11] - The company is focusing on two pivotal-stage CELMoDs (Iberdomide and Mezigdomide) and next-generation CAR-T assets [12][13] CELMoDs Development - Iberdomide and Mezigdomide are positioned to become foundational treatments in multiple myeloma, with enhanced potency and immune stimulation [12][13] - Iberdomide has shown a 95% overall response rate and a 68% complete response rate in early trials, indicating significant clinical benefits [15][16] - Mezigdomide demonstrated over 80% overall response rates in pretreated patients, showcasing its potential in combination therapies [17][18] Combination Therapies - BMS is exploring novel combinations of CELMoDs with other therapies, including CAR-T and bispecifics, to enhance treatment efficacy [19][20] - The company is optimistic about the potential of CELMoDs to improve outcomes when used as preconditioning agents or maintenance therapies post-CAR-T infusion [20][21] CAR-T Therapy Advancements - ArloCell, a GPRC5D targeting CAR-T, has shown promising results with over 90% overall response rates in heavily pretreated patients [22][23] - The dual-targeting BCMA and GPRC5D CAR-T is expected to provide more durable and potent activity compared to single-target therapies [24][25] Lymphoma Assets - BMS is developing novel lymphoma assets, including golcadomide and a BCL6 targeting ligand-directed degrader, which have shown promising efficacy results [26][27][31] - The company aims to improve cure rates in large B-cell lymphoma and pursue functional cures in follicular lymphoma [26][27] Regulatory and Market Considerations - BMS is preparing for potential accelerated approval of Iberdomide based on MRD results, with ongoing discussions with health authorities [41][42] - The approval of Blenrep is viewed positively, providing additional treatment options for patients, although its use may be limited in earlier lines of therapy [52][53] Future Outlook - BMS anticipates significant data readouts in the coming years that will shape the future growth of the company and its hematology portfolio [32][33] - The company is positioned to transform the treatment landscape for hematological diseases, with a focus on innovative therapies that address unmet patient needs [32][33] Additional Important Insights - The company is utilizing AI and machine learning to enhance its R&D processes and expedite treatment delivery [6] - BMS is committed to ensuring that no patient segment is left behind, focusing on personalized treatment approaches [25][32] - The evolving treatment landscape for multiple myeloma is complex, but BMS aims to integrate its portfolio to provide comprehensive care [47][50]

Core Insights - Bio-Techne has a rich history of 50 years, with a core business that includes 7,000 proteins and 400,000 antibodies, serving as essential components for life science tools and laboratory research [2] - Over the past decade, Bio-Techne has focused on leveraging its components in faster-growing application areas, specifically in cell therapy and proteomics [3] Application Areas - The first application area is cell therapy, which involves growing immune or regenerative cells to treat diseases, supported by the necessary core components and bioreactor technology [3] - The second application area is proteomics, which is centered around proteomic analysis, although further details were not provided in the excerpt [4]